RGC

Regencell Bioscience

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

County of HQ

Hong Kong

Next Earnings Date

01/30/26

Business Summary

Regencell Bioscience operates within the specialty pharmaceutical segment, developing and commercializing treatments that target niche therapeutic areas. The business model is inherently high-risk, relying on clinical development success and regulatory approval to unlock commercial revenue streams. Cash generation, when it occurs, would likely stem from proprietary formulations, licensing agreements, or premium pricing within specialized indications. The moat, if it materializes, would depend on intellectual property protection and regulatory exclusivity rather than scale efficiency, making execution and capital discipline critical determinants of long-term value creation.

 


Analyze RGC on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$14,251

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

500+

EV / EBITDA

-4218.50

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.01

Next Year EPS Growth Estimate

-

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-73.70%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0.1

Piotroski F-Score

1

Altman Z-Score

9543.10

Return on Invested Capital (ROIC)

-52.30%

Current Ratio

7.4

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze RGC on TradingView

Gainseekers Quantitative Analysis

Summary

At a $14,251M market cap with EPS of -4,218.50, operating margin of -73.70%, and ROIC of -52.30%, this is not a growth story — it is a capital destruction story priced like a premium asset. The absence of a P/E, Forward P/E, and PEG confirms there is no earnings base to value, while a Price/Book above 500+ signals extreme multiple expansion untethered from fundamentals. The only statistical bright spot is an Altman Z-Score of 9,543.10 and a current ratio of 7.4, implying overwhelming balance sheet safety despite catastrophic profitability. This is not a mispricing in the traditional sense; it is a speculation vehicle trading at an extraordinary premium to its accounting base with zero evidence of operational efficiency.

AI Exposure / Tech Reliance

As a Specialty & Generic Drug Manufacturer in Healthcare, the company operates in a sector where AI increasingly drives drug discovery, trial optimization, and cost efficiency. However, with operating margins at -73.70%, the data suggests it has not yet translated industry-level technological tailwinds into economic gains. Until profitability metrics inflect, AI exposure remains theoretical rather than financially visible.

The Bull Case

A speculative bull case rests almost entirely on financial survivability and optionality. The Altman Z-Score of 9,543.10 and current ratio of 7.4 indicate exceptional short-term solvency, meaning bankruptcy risk appears negligible despite heavy losses. For aggressive investors, the projected EPS improvement to -$0.01 next year suggests a dramatic earnings inflection could occur if estimates materialize, creating asymmetric upside from a deeply negative base. In that scenario, today’s extreme Price/Book above 500+ becomes a forward-looking bet on normalization rather than a reflection of current fundamentals, with institutional sentiment implied by a 1.10% consensus rating supporting speculative optimism.

The Bear Case

The bear case is overwhelming. A Piotroski F-Score of 1 signals severe fundamental weakness, while ROIC of -52.30% confirms management is destroying capital at scale. Operating margins at -73.70% and EPS of -4,218.50 show a business model currently incapable of generating sustainable earnings, and the absence of meaningful valuation metrics like P/E or PEG (both listed as -) eliminates any traditional framework for justifying a $14,251M valuation. A Price/Book over 500+ is not aggressive — it is extreme — and without positive returns on equity or operating leverage, this structure resembles a highly priced narrative rather than an investable cash-flow compounder.

Market Sentiment & Smart Money

Short Interest %

1.10%

Analyst Consensus

-

Average Analyst Price Target

-

Institutional Ownership %

0.10%

1-Year Beta

1.09

Insider Buying % (6 Mo)

88.60%%

Distance to 52-Week High

3.00%

Distance to 52-Week Low

306.90%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.